Viropro, Inc. (VPRO)

[The Rainmaker]

VPRO: If you are in this stock you should read this very carefully....

If VPRO makes make deals with 3 companies they will see $6.9 million in revenues over three years. $6.9 million in Revenues not even profit. They made one deal out of the three so far...so you are looking at $2.3 million dollars in revenue over the next 36 months with today's Spencer deal.....The first revenue isn't even coming until 2012 for a deal they signed in 2007 with Intas. So 2011 deal with Spectrum, first revenue coming in 2014??? Even when it comes it's not even very much money, $2.3 million per deal per the company.

So far, Viropro has focused on the development of a biosimilar version of Rituximab and has already reached an agreement for the manufacturing and sale of this biosimilar with Intas Biopharmaceuticals. The company is in discussions with three other groups for agreements that would represent revenues USD 6.9 million.

Moreover, Intas plans to market its generic Rituximab within the next 12-18 months, which means royalties will be payable to Viropro starting in FY2012.